

Supplementary Table 1 Odds ratios of effect of treatment on magnitude of decline from baseline for ADAPT visits only

Measure	Celecoxib n / N	Naproxen n / N	Placebo n / N	Celecoxib vs Placebo		Naproxen vs Placebo	
				OR* (95% CI)	p-value	OR* (95% CI)	p-value
Global summary							
≥0.25 point decline	219/664	211/646	319/970	1.00 (0.81, 1.24)	0.99	0.99 (0.80, 1.23)	0.95
≥0.50 point decline	113/664	114/646	154/970	1.08 (0.83, 1.41)	0.55	1.14 (0.87, 1.49)	0.37
≥0.75 point decline	54/664	55/646	74/970	1.07 (0.74, 1.55)	0.71	1.13 (0.78, 1.62)	0.53
≥1.00 point decline	31/664	33/646	50/970	0.90 (0.57, 1.42)	0.64	0.99 (0.63, 1.56)	0.97
≥1.25 point decline	22/664	22/646	30/970	1.07 (0.61, 1.88)	0.81	1.10 (0.63, 1.93)	0.73
Adjusted 3MS-E							
≥5 point decline	100/664	103/646	140/970	1.05 (0.79, 1.38)	0.75	1.13 (0.85, 1.49)	0.39
≥6 point decline	80/664	69/646	103/970	1.15 (0.84, 1.57)	0.38	1.01 (0.73, 1.39)	0.97
≥7 point decline	59/664	51/646	72/970	1.21 (0.85, 1.71)	0.30	1.07 (0.73, 1.55)	0.74
≥8 point decline	49/664	41/646	51/970	1.43 (0.95, 1.23)	0.08	1.22 (0.80, 1.87)	0.36
≥9 point decline	33/664	33/646	40/970	1.21 (0.76, 1.95)	0.42	1.25 (0.78, 2.01)	0.36

n: number of events; N: number of people at risk; OR: odds ratio; CI: confidence interval; 3MS-E: Modified Mini-Mental State Examination

*Calculated using logistic regression with the binary outcome of decline of given magnitude at any follow-up visit after adjusting for clinic and age strata. P-values are from Wald χ^2 test.